These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 31476416)

  • 1. A discussion of potential clinical markers predicting anti-inflammatory treatment response in individuals with major depression.
    Brietzke E; Booij L; Wieck A; Ricci A; Soares CN; Roberts N; Khalid-Khan S
    Brain Behav Immun; 2020 Jan; 83():3-4. PubMed ID: 31476416
    [No Abstract]   [Full Text] [Related]  

  • 2. [The relation between depression and inflammation].
    Fisker L; Köhler-Forsberg O; Hageman I
    Ugeskr Laeger; 2018 May; 180(20):. PubMed ID: 29761778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is depression an inflammatory disorder?
    Raison CL; Miller AH
    Curr Psychiatry Rep; 2011 Dec; 13(6):467-75. PubMed ID: 21927805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of anti-inflammatory treatment interventions on depression in individuals with major depressive disorder and high levels of inflammation: A systematic review of randomized clinical trials.
    Allison DJ; Sharma B; Timmons BW
    Physiol Behav; 2019 Aug; 207():104-112. PubMed ID: 31078670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammatory depression: a trifecta of trouble.
    Raison CL
    J Clin Psychiatry; 2014 Jun; 75(6):663-4. PubMed ID: 25004190
    [No Abstract]   [Full Text] [Related]  

  • 6. The immunomodulatory effect of ketamine in depression.
    Szałach ŁP; Lisowska KA; Słupski J; Włodarczyk A; Górska N; Szarmach J; Jakuszkowiak-Wojten K; Gałuszko-Węgielnik M; Wiglusz MS; Wilkowska A; Cubała WJ
    Psychiatr Danub; 2019 Sep; 31(Suppl 3):252-257. PubMed ID: 31488736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological aspects of the treatment of depression and schizophrenia.
    Müller N
    Dialogues Clin Neurosci; 2017 Mar; 19(1):55-63. PubMed ID: 28566947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blocking the trigger: An integrative view on the anti-inflammatory therapy of depression.
    Su WJ; Cao ZY; Jiang CL
    Brain Behav Immun; 2019 Nov; 82():10-12. PubMed ID: 31493446
    [No Abstract]   [Full Text] [Related]  

  • 9. Inflammatory Profiles in Depressed Adolescents Treated with Fluoxetine: An 8-Week Follow-up Open Study.
    Pérez-Sánchez G; Becerril-Villanueva E; Arreola R; Martínez-Levy G; Hernández-Gutiérrez ME; Velasco-Velásquez MA; Alvarez-Herrera S; Cruz-Fuentes C; Palacios L; de la Peña F; Pavón L
    Mediators Inflamm; 2018; 2018():4074051. PubMed ID: 30662368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relevance of the anti-inflammatory properties of curcumin in neurodegenerative diseases and depression.
    Tizabi Y; Hurley LL; Qualls Z; Akinfiresoye L
    Molecules; 2014 Dec; 19(12):20864-79. PubMed ID: 25514226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cytokine network in the pathogenesis of major depressive disorder. Close to translation?
    Petralia MC; Mazzon E; Fagone P; Basile MS; Lenzo V; Quattropani MC; Di Nuovo S; Bendtzen K; Nicoletti F
    Autoimmun Rev; 2020 May; 19(5):102504. PubMed ID: 32173514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of anti-inflammatory agents for the treatment of major depressive disorder: a systematic review and meta-analysis of randomised controlled trials.
    Bai S; Guo W; Feng Y; Deng H; Li G; Nie H; Guo G; Yu H; Ma Y; Wang J; Chen S; Jing J; Yang J; Tang Y; Tang Z
    J Neurol Neurosurg Psychiatry; 2020 Jan; 91(1):21-32. PubMed ID: 31658959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammatory cytokines, growth factors, and depression.
    Lotrich F
    Curr Pharm Des; 2012; 18(36):5920-35. PubMed ID: 22681170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Inflammatory Treatments for Major Depressive Disorder: What's on the Horizon?
    Jha MK
    J Clin Psychiatry; 2019 Jun; 80(6):. PubMed ID: 31237996
    [No Abstract]   [Full Text] [Related]  

  • 15. Targeting the inflammatory pathway as a therapeutic tool for major depression.
    Noto C; Rizzo LB; Mansur RB; McIntyre RS; Maes M; Brietzke E
    Neuroimmunomodulation; 2014; 21(2-3):131-9. PubMed ID: 24557046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minocycline as an adjunct for treatment-resistant depressive symptoms: study protocol for a pilot randomised controlled trial.
    Husain MI; Chaudhry IB; Rahman RR; Hamirani MM; Qurashi I; Khoso AB; Deakin JF; Husain N; Young AH
    Trials; 2015 Sep; 16():410. PubMed ID: 26374703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammatory mechanisms in major depressive disorder.
    Raedler TJ
    Curr Opin Psychiatry; 2011 Nov; 24(6):519-25. PubMed ID: 21897249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-inflammatory treatments for mood disorders: Systematic review and meta-analysis.
    Husain MI; Strawbridge R; Stokes PR; Young AH
    J Psychopharmacol; 2017 Sep; 31(9):1137-1148. PubMed ID: 28858537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Major Depressive Disorder in Older Patients as an Inflammatory Disorder: Implications for the Pharmacological Management of Geriatric Depression.
    Forbes MP; O'Neil A; Lane M; Agustini B; Myles N; Berk M
    Drugs Aging; 2021 Jun; 38(6):451-467. PubMed ID: 33913114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood-based biomarkers predicting response to antidepressants.
    Busch Y; Menke A
    J Neural Transm (Vienna); 2019 Jan; 126(1):47-63. PubMed ID: 29374800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.